| Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. | |
| | |
MedLine Citation:
|
PMID: 20953817 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
We sought to evaluate the association between C-reactive protein (CRP) sampled on admission and short- and long-term mortality in patients with acute coronary syndromes (ACS) undergoing early invasive treatment. Baseline levels of CRP were determined in 2,974 patients with moderate and high-risk ACS undergoing an early invasive treatment strategy in the large-scale randomized ACUITY trial. The relationship of CRP to 30-day and 1-year clinical outcomes were assessed according to quartiles of CRP values. Patients with CRP levels in the fourth quartile compared to the first quartile had significantly higher 30-day mortality (2.3 vs. 0.3%, P = 0.0004) and 1-year mortality (5.5 vs. 2.8%, P = 0.0003). CRP level as a continuous variable was associated with 30-day mortality (OR [95% CI] for one unit increase in logarithmically transformed CRP level = 1.42 [1.08-1.89], P = 0.01) and 1-year mortality (OR [95% CI] = 1.24, [1.04-1.47], P = 0.02). By multivariable analysis, higher baseline CRP levels independently predicted 30-day and 1-year mortality, a relationship that was particularly strong for patients with the highest quartile of CRP (OR [95% CI] = 5.19 [1.14-23.68], P = 0.009). In troponin-positive patients, increasing quartiles of CRP were associated with a trend for 30-day mortality (P (trend) = 0.08) and a significant increase in 1-year mortality (P (trend) = 0.02); this relationship was not present in troponin-negative patients. Baseline CRP level is a powerful independent predictor of both early and late mortality in patients with ACS being treated with an early invasive strategy, especially in troponin positive patients. |
| | |
Authors:
|
Adriano Caixeta; Gregg W Stone; Roxana Mehran; Edwin A Lee; Brent T McLaurin; David A Cox; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; Harvey D White; E Magnus Ohman; Tullio Palmerini; George Syros; Christos Kittas; Martin Fahy; W Craig Hooper; Alexandra J Lansky; George D Dangas |
Related Documents
:
|
10583227 - Plasma il-8 and il-6 levels can be used to define a group with low risk of septicaemia ... 17130267 - Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with ch... 12229967 - Lack of correlation between disease activity and decreased stimulated secretion of il-1... 7926977 - Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syn... 12048147 - Personality dimensions and neuropsychological performance in first-degree relatives of ... 15974367 - Reliability and validity of a twelve-minute walking test for coronary heart disease pat... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of thrombosis and thrombolysis Volume: 31 ISSN: 1573-742X ISO Abbreviation: J. Thromb. Thrombolysis Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502018 Medline TA: J Thromb Thrombolysis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 154-64 Citation Subset: IM |
Affiliation:
|
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti-leukemic activity of Dasatinib in both p53(wild-type) and p53 (mutated) B malignant ce...
Next Document: Interleukin-10 -1082 promoter polymorphism and gastric cancer risk in a Chinese Han population.